| CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery (NCT01766219) | Wake Forest University Health Sciences | 2013-05-01 |
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery (NCT01859182) | National Cancer Institute (NCI) | 2013-01-01 |
| Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer (NCT01282333) | National Cancer Institute (NCI) | 2011-01-01 |
| Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers (NCT01229111) | National Cancer Institute (NCI) | 2010-10-01 |
| Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery (NCT00553332) | National Cancer Institute (NCI) | 2007-11-01 |
| Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery (NCT00478140) | National Cancer Institute (NCI) | 2007-05-01 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (NCT00397384) | National Cancer Institute (NCI) | 2007-01-01 |
| Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors (NCT00356889) | National Cancer Institute (NCI) | 2006-05-01 |
| Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer (NCT00107536) | National Cancer Institute (NCI) | 2005-10-01 |
| S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma (NCT00238212) | National Cancer Institute (NCI) | 2005-10-01 |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery (NCT00101036) | National Cancer Institute (NCI) | 2004-11-01 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (NCT00087191) | National Cancer Institute (NCI) | 2004-05-01 |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder (NCT00085410) | National Cancer Institute (NCI) | 2004-01-01 |
| Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer (NCT00033462) | National Cancer Institute (NCI) | 2002-03-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer (NCT00023946) | National Cancer Institute (NCI) | 2001-08-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery (NCT00253617) | Jonsson Comprehensive Cancer Center | |